Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | CCR5 | P51681 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182313 | 0.86 | GPR88 (0.49) | ROCK2ROCK1CTSSCTSKCTSL | |
| SCHEMBL3182322 | 0.86 | GPR88 (0.49) | ROCK2ROCK1CTSSCTSKCTSL | |
| Ethylene SCHEMBL6701227 | 0.86 | UTS2R (0.44) | UTS2RROCK2ROCK1CCR5CTSS | |
| SCHEMBL20252510 | 0.84 | CTSK (0.48) | ROCK2ROCK1CTSSCTSKCTSL | |
| SCHEMBL5406355 | 0.83 | RAB9A (0.50) | CTSSCTSKNPC1 | |
| SCHEMBL5404729 | 0.83 | RAB9A (0.50) | CTSSCTSKNPC1 | |
| SCHEMBL14440789 | 0.82 | CCR5 (0.50) | CCR5CTSSCTSK | |
| SCHEMBL13326683 | 0.82 | CCR5 (0.50) | CCR5CTSSCTSK | |
| SCHEMBL20045534 | 0.81 | HPGD (0.46) | CTSSCTSKCTSL | |
| SCHEMBL5634305 | 0.81 | CTSL (0.51) | CCR5CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | UTS2R 1154/4885ROCK2 493/4885ROCK1 475/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | UTS2R 1154/4885ROCK2 493/4885ROCK1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.